.png "Global Blood Therapeutics (NASDAQ: GBT)")
Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (NASDAQ: GBT) today and set a price target of $70. The company’s shares opened today at $40.60.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 44.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Miragen Therapeutics Inc.
Currently, the analyst consensus on Global Blood Therapeutics is Strong Buy and the average price target is $72.13, representing a 77.7% upside.
In a report issued on June 15, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $69 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.05 and a one-year low of $24.03. Currently, Global Blood Therapeutics has an average volume of 743.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.
Read More on GBT:
